Last reviewed · How we verify
NCT06809270
Moderate Intensity Intermittent Walking in Postmenopausal Women
NA trial testing Walking training intervention in Liver Enzymes in 36 participants. Completed in 22 December 2024.
22 December 2024
Quick facts
| Lead sponsor | Wissal Abassi |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 36 |
| Start date | 23 September 2024 |
| Primary completion | 22 December 2024 |
| Estimated completion | 22 December 2024 |
| Sites | 1 location across Tunisia |
Drugs / interventions tested
- Walking training intervention
Conditions studied
- Liver Enzymes — all drugs for Liver Enzymes →
- Inflammatory Markers — all drugs for Inflammatory Markers →
Sponsor
Wissal Abassi
Who can join
Adults 50 to 60, female only, with Liver Enzymes or Inflammatory Markers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to investigate the impact of a walking training intervention program on liver enzymes and selected inflammatory markers in postmenopausal women with obesity. The main question it aims to answer is: Does walking training reduce the risk of liver disease by modulating hepatic-enzymes and selected inflammatory markers? Researchers will compare walking training intervention (designed to the experimental group) to non-training intervention (designed to the control group) to see if the training program works to improve liver health in obese postmenopausal women. Participants in the experimental (training) group will: underwent a moderate intensity intermittent walking training (MIWT) at 60% to 80% of the 6-min-walking-test distance, four times a week of 60 min/session. Participants in control group will : not perform any physical training and maintain their usual daily activities.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Moderate-Intensity Intermittent Walking Improves Liver-Related Biomarkers and Reduces Inflammation in Postmenopausal Women With Obesity: A Randomized Controlled Study.
Abassi W, Ouerghi N, Muscella A, Feki M, et al · · 2026 · PMID 41732828 · DOI 10.1002/ejsc.70147
Verify or expand the search:
- PubMed search for NCT06809270
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Wissal Abassi trials
Trials by the same sponsor.
- NCT07019285 — Interval Training and Plasma Volume Variation · NA · completed
- NCT07074132 — Physical Activity and Quality of Life in Postmenopausal Women · NA · completed
- NCT06905236 — Kidney Function in Obese Women · NA · completed
- NCT06793345 — Walking Training Improves Thyroid and Cardiometabolic Markers in Postmenopausal Obesity · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06809270 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wissal Abassi
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06809270.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing